

Imfinzi durvalumab Global Market Report 2025: Key Drivers, Trends, Growth Opportunities, And Forecast

The Business Research Company's Imfinzi (durvalumab) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, January 20, 2025 /EINPresswire.com/ -- The global imfinzi durvalumab market has experienced notable growth in recent



years, showing promising signs of continuing this trend. Its market size is set to climb from \$2,701.22 million in 2024 to \$3,013.33 million in 2025, equating to a compound annual growth rate CAGR of 11.6%. This historic growth owes itself to a variety of factors, primarily expanded indications and approvals, increased demand for targeted and personalized therapies,



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research company

improvements in immunotherapy and a surge in patient demand for immunotherapies.

How Big Is The Global Imfinzi Durvalumab Market Expected To Grow, And What Is Its Annual Growth Rate?

Looking forward, the imfinzi durvalumab market is expected to maintain its rapid ascension, growing to \$4,143.36 million in 2029 at a CAGR of 11.3%. The underlying drivers include growing acceptance of immunotherapy, rising prevalence of cancer, increasing

use of combination therapies, and an augmented investment in healthcare facilities.

Get Your Free Sample of The <u>Imfinzi Durvalumab Market Report</u> <u>https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp</u>

What Is Driving the Growth of the Imfinzi Durvalumab Market?

Considering key growth drivers, the growing incidence of cancer is projected to fuel the imfinzi durvalumab market. Cancer, a group of diseases characterized by uncontrolled growth and spread of abnormal cells which can destroy healthy tissues, has seen increased incidence rates due to an aging population and harmful lifestyle habits. Imfinzi durvalumab is used to treat cancer by inhibiting the PD-L1 protein and thereby preventing the evasion of the immune system by cancer cells.

In addition, the rise of personalized medicine is instrumental in propelling the growth of the imfinzi durvalumab market. Imfinzi durvalumab, by targeting and inhibiting the PD-L1 protein, enables tailored immunotherapy treatments for cancer patients based on the specific tumor biology and immune system characteristics.

Which Leading Companies Are Driving The Growth Of The <u>Imfinzi Durvalumab Market Share</u>? Major companies operating in the imfinzi durvalumab market, of which AstraZeneca PLC is a primary player, have contributed enormously to these growth trends.

The imfinzi durvalumab market is seeing an emerging trend of regulatory approvals to expand usage for additional cancer types and enhance clinical indications in order to increase market reach. For instance, AstraZeneca received FDA approval for durvalumab Imfinzi for treating locally advanced or metastatic biliary tract cancer BTC in adults in September 2022, based on the results of the TOPAZ-1 trial.

How Is the Global Imfinzi Durvalumab Segmented?

In terms of market segmentation, the imfinzi durvalumab market is classified by type into 2.4mL injection and 10mL injection. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. It's applications are locally advanced urothelial carcinoma, metastatic urothelial carcinoma, and other applications.

The Leading Region In The Imfinzi Durvalumab Market

North America held dominion as the largest region in the imfinzi durvalumab market in 2024. However, Asia-Pacific is set to rank as the most rapidly growing region in the forecast period. Other encompassed regions are Western Europe, Eastern Europe, South America, Middle East, and Africa.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report

Browse more similar reports-

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Hyperimmune Globulins Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hyperimmune-globulins-global-market-report

About The Business Research Company

The Business Research Company, with over 15000+ reports from 27 industries covering 60+ geographies, is a dependable entity for comprehensive, data-replete research and insights. A vast repository of 1,500,000 datasets, a solid foundation of in-depth secondary research, and a wealth of unique insights from industry leaders serve to equip you with invaluable information for superiority in your field.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:

Facebook

Χ

LinkedIn

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.